295 related articles for article (PubMed ID: 33432066)
1. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
5. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
[TBL] [Abstract][Full Text] [Related]
7. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
[TBL] [Abstract][Full Text] [Related]
10. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
11. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
[TBL] [Abstract][Full Text] [Related]
12. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
13. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
16. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
17. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
[TBL] [Abstract][Full Text] [Related]
18. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
19. Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.
Hayashi T; Yoshida Y; Yamada T; Tanaka K; Shimaoka H; Kajitani R; Munechika T; Nagano H; Matsumoto Y; Komono A; Sakamoto R; Aisu N; Yoshimatsu G; Yoshimura F; Hasegawa S
Cancer Med; 2022 Aug; 11(16):3126-3135. PubMed ID: 35312176
[TBL] [Abstract][Full Text] [Related]
20. Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases.
Liu M; Bao Q; Zhao T; Huang L; Zhang D; Wang Y; Yan X; Wang H; Jin K; Liu W; Wang K; Xing B
Hepatol Int; 2024 Jun; 18(3):1029-1039. PubMed ID: 38427145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
